Overall, our findings reveal a key role of PAK kinase in STAT3/5‐mediated oncogene induction, which should be further exploited for the treatment of L‐CTCL. The gene discussed is STAT3; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.